Oral Versus IV Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Endoscopic hemostasis has been documented by a number of clinical studies to be effective in
decreasing rebleeding, need for emergency surgery, and hospitalization days. Studies showed
adjuvant treatment with proton pump inhibitor (PPI) after initial endoscopic hemostasis
reduced recurrent ulcer bleeding. However, the optimal dose and route of adjuvant PPI therapy
remains controversial. A recent study demonstrated frequent oral PPI offered similar acid
control as currently recommended intravenous infusion PPI did in patients with bleeding
ulcers. The investigators hypothesize that an frequent oral PPI treatment has similar benefit
as proton pump inhibitor infusion in patient with bleeding ulcers after combined endoscopic
hemostasis.